A novel anti-proliferative macromolecular conjugate, CS-g-MMCs, was synthesized in order to decrease the cytotoxicity of Mitomycin C (MMC) which was a traditional anti-proliferative agent of fibroblast in trabeculectomy. The structure of CS-g-MMCs was characterized by (1)H NMR, FT-IR spectroscopy and GPC analysis. The grafting degree (dg) of MMC onto chitosan (CS) was determined to be in the range of 2.8-11.3%, which could be controlled by variation of the molar ratios of MMC to oxidized chitosan (CS-CHO). In the drug release profiles of CS-g-MMCs in vitro, an initial burst followed by slow leakage was observed, and addition of acid or lysozyme obviously accelerated the MMC release. The MTS assay indicated that CS-CHO of 8 mg/ml has no cytotoxicity against human Tenon's capsule fibroblasts (HTCFs). The inhibition of HTCFs proliferation by CS-g-MMCs increased along with increasing the dg of conjugate. The CS-g-MMCs also caused the apoptosis of HTCFs and interfered in the active DNA synthesis in HTCFs. Furthermore, the expression of a-SMA at gene and protein levels were obviously lower when HTCFs were treated with CS-g-MMCs, as compared to MMC or blend of MMC/CS-CHO (p<0.05). Our results primarily demonstrated that the CS-g-MMCs conjugates have low cytotoxicity and have the effect to inhibit fibroblast proliferation.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.ejps.2012.02.023 | DOI Listing |
Food Funct
January 2025
Givaudan France Naturals, Avignon, France.
Curcuminoid absorption can be influenced by the presence of additional compounds, but there has been no study investigating this in a robust manner. The aim of this clinical trial was to assess the effect of the type of food matrix on the absorption of curcuminoids from a highly bioavailable turmeric formulation. Participants consumed the turmeric formulation in the form of capsules, a ready-to-drink fruit nectar, a sports nutrition bar, a dairy analogue (oat milk), pectin gummies, and a probiotic drink in a randomized, crossover study.
View Article and Find Full Text PDFOphthalmic Plast Reconstr Surg
October 2024
Jones Eye Institute, University of Arkansas for Medical Sciences, Little Rock, Arkansas, U.S.A.
Purpose: To evaluate the long-term outcomes of enucleation without conjunctival closure in a large patient cohort.
Methods: A retrospective chart review was conducted from January 2011 to January 2024, examining 144 eyes of 143 patients who underwent enucleation without conjunctival closure by a single oculoplastic surgeon. Data collected included patient demographics, indications for surgery, implant types, and complications.
Indian J Ophthalmol
December 2024
Department of Ophthalmology, Military Hospital, Panagarh, West Bengal, India.
We describe a novel technique for recurrent pterygium and assess the advantage of properties of extended tenonectomy, amniotic membrane transplantation, and limbal epithelial transplantation in terms of recurrence rate, postoperative symptoms, postoperative orthoptics, and other complications. A total of nine eyes with recurrent pterygium underwent PERMISLET, i.e.
View Article and Find Full Text PDFBMJ Case Rep
November 2024
Cornea and Anterior Segment, LV Prasad Eye Institute Bhubaneswar Campus, Bhubaneswar, India
Management of corneal perforation depends on the size, location and cause of the lesion. Smaller perforations can be managed with tissue adhesives (TAs), amniotic membrane transplantation or Tenon's patch graft (TPG). Tenon's capsule is an autologous transplant and, as such, does not require to be supplied by an eye bank support.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!